InnoCare's TL1A / IL-23p19 bispecific antibody ICP-B161 approved for clinical trials

InnoCare Pharma announced on October 12 that its independently developed novel bispecific antibody targeting TL1A and IL-23p19 has been approved by the Center for Drug Evaluation of the National Medical Products Administration to conduct clinical trials for the treatment of inflammatory bowel disease and other autoimmune diseases.